AC Immunity Shares Soar on Exclusive License Deal with Takeda
By Dean Seal
Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license its active immunotherapy for Alzheimer's disease.
The stock was up 64% at $3.80 in premarket trading. Shares had fallen by more than 50% year-to-date when the market closed Friday.
The biopharmaceutical company said Monday morning that Takeda will receive an exclusive option to license global rights to ACT-24.060, AC Immune's active immunotherapy designed to delay or slow Alzheimer's disease progression.
AC Immune is set to receive an upfront payment of $100 million upon closing and be eligible for additional milestone payments of up to $2.1 billion.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 13, 2024 07:26 ET (11:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks